Skip to main content

Advertisement

Figure 4 | Arthritis Research & Therapy

Figure 4

From: Serum level of soluble CX3CL1/fractalkine is elevated in patients with polymyositis and dermatomyositis, which is correlated with disease activity

Figure 4

Serum level of CX3CL1 in patients with polymyositis, patients with dermatomyositis and healthy controls. Serum samples were collected from polymyositis (PM) patients (n = 7), dermatomyositis (DM) patients (n = 22) and healthy controls (n = 20). (A) Concentration of serum soluble CX3CL1 measured by ELISA. Values are mean ± standard error of the mean. (B) CX3CL1 levels before and after treatment in PM and DM patients (n = 14; three PM patients and 11 DM patients). Symbols joined by a solid line represent data from an individual subject.

Back to article page